(A) Frequency distribution of mitotic durations (measured from NEB to anaphase onset) of cells treated with DMSO (n = 100), 1 μM MK-1775 (n = 105), or CHX plus 1 μM MK-1775 (n = 54) during G2 phase. Cells were considered to exhibit a protracted mitosis if the mitotic duration exceeded the 95th percentile of the mitotic duration of DMSO-treated cells (>39.5 min). p values were calculated using a nonparametric Mann-Whitney test (****p < 0.0001).
(B) Frequency distribution of mitotic durations (measured from NEB to anaphase onset) of cells treated with DMSO (n = 113), 1 μM PD0166285 (n = 100), or CHX plus 1 μM PD0166285 (n = 110) during G2 phase. Cells were considered to exhibit a protracted mitosis if the mitotic duration exceeded the 95th percentile of the mitotic duration of DMSO-treated cells (>30 min). p values were calculated using a nonparametric Mann-Whitney test (*p < 0.05 and ****p < 0.0001).
(C) Mitotic duration was measured for cells that progressed through G2 phase and entered mitosis in the presence of DMSO or different concentrations of MK-1775 or PD0166285. Mitotic duration increased with higher concentrations of MK-1775 or PD0166285 (and shorter G2 duration; see Figures 3B and 4A).
(D) Frequency distribution of mitotic durations of cells treated with DMSO (n = 99), SB202190 (n = 88), SB203580 (n = 88), CHX+SB202190 (n = 76), or CHX+SB203580 (n = 77) during G2 phase. Cells were considered to exhibit a protracted mitosis if the mitotic duration exceeded the 95th percentile of the mitotic duration of DMSO-treated cells (>30 min). p values were calculated using a nonparametric Mann-Whitney test.